Key facts
- ProteoBridge’s last known valuation is $11.1M (Sep 2025).
- It has raised $1.9M; the latest was Later Stage VC ($550K) in Sep 2025.
- Notable investors include Mirai Creation Capital, JMTC Capital.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for ProteoBridge
- ·The full record, as it builds
Funding rounds
No funding rounds for ProteoBridge are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ProteoBridge
Provider of Vivo reactions on protein arrays intended to deliver innovative research approach. The company's platform performs high-precision immune profiling based on the resources and developed technologies established by the National Institute of Advanced Industrial Science and Technology, enabling researchers to study drug discovery, regenerative medicine, and diagnosis.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2018
- Employees
- 20
- Website
- proteo-bridge.co.jp/
- Ownership
- Privately Held (backing)
ProteoBridge doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ProteoBridge shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ProteoBridge in its N-PORT filings yet. We sweep new filings monthly.